Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial Tract

A Phase II Monocentric Study of Oxaliplatin in Combination With Gemcitabine in Patients With Advanced/Metastatic Transitional Cell Carcinoma of the Urothelial Tract

This is a phase II monocentric study of oxaliplatin (Ox) in combination with gemcitabine (Gem; GEMOX) in patients (pts) with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract.

Inclusion Criteria:

• Transitional cell carcinoma
• Histologically-proven
• Locally advanced unresectable or metastatic
• With at least one measurable target
• Informed consent signed

Exclusion Criteria:

• Previous chemotherapy
• Previous radiotherapy
• Performance status >=2
• Peripheral neuropathy >=1